Pain management in opioid maintenance treatment

References

• United Nations Office on Drugs and Crime. World Drug Report 2016. New York (NY): United Nations; 2016.
   Google Scholar
• Jones CM, Logan J, Gladden RM, et al. Vital signs: demographic and substance use trends among heroin users - United States, 2002–2013. MMWR Morb Mortal Wkly Rep. 2015;64(26):719–725.
   PubMed Web of Science ®Google Scholar
• EMCDDA. European Drug Report 2016: Trends and developments. Lisbon: EMCDDA; 2016. Available from: http://www.emcdda.europa.eu/publications/edr/trends-developments/2014.
   Google Scholar
• Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358–367.
   PubMed Web of Science ®Google Scholar
• Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375(16):1596–1597.
   PubMedGoogle Scholar
• Lieb MWH, Palm U, Apelt SM, et al. Psychiatric comorbidity in substitution treatment of opioid-dependent patients in primary care: prevalence and impact on clinical features. Heroin Addict Relat Clin Probl. 2010;12(4):5–16.
   Web of Science ®Google Scholar
• Soyka M, Kranzler HR, van Den Brink W, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorder. Part 2: opioid dependences. World J Biol Psychiatry. 2011;12(3):160–187.
   PubMed Web of Science ®Google Scholar
• Mammen K, Bell J. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin Pharmacother. 2009;10(15):2537–2544.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3:Cd002209.
   PubMed Web of Science ®Google Scholar
• Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1–171, iii-iv.
   Web of Science ®Google Scholar
• Soyka M, Zingg C, Koller G, et al. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol. 2008;11(5):641–653.
   PubMed Web of Science ®Google Scholar
• Soyka M, Strehle J, Rehm J, et al. Six-year outcome of opioid maintenance treatment in heroin-dependent patients: results from a naturalistic study in a nationally representative sample. Eur Addict Res. 2017;23(2):97–105.
   PubMed Web of Science ®Google Scholar
• Sharon H, Goldway N, Goor-Aryeh I, et al. Personal experience and attitudes of pain medicine specialists in Israel regarding the medical use of cannabis for chronic pain. J Pain Res. 2018;11:1411–1419.
   PubMed Web of Science ®Google Scholar
• Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019;13(2):93–103.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Comer SD, Lofwall MR, et al. Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74(9):894–902.
   PubMed Web of Science ®Google Scholar
• Fareed A, Vayalapalli S, Casarella J, et al. Effect of buprenorphine dose on treatment outcome. J Addict Dis. 2012;31(1):8–18.
   PubMed Web of Science ®Google Scholar
• Hser YI, Evans E, Huang D, et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016;111(4):695–705.
   PubMed Web of Science ®Google Scholar
• Haber PS, Elsayed M, Espinoza D, et al. Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. Drug Alcohol Depend. 2017;181:132–139.
   PubMed Web of Science ®Google Scholar
• Saxon AJ, Ling W, Hillhouse M, et al. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013;128(1–2):71–76.
   PubMed Web of Science ®Google Scholar
• Soyka M, Backmund M, Schmidt P, et al. Buprenorphine-naloxone treatment in opioid dependence and risk of liver enzyme elevation: results from a 12-month observational study. Am J Addict. 2014;23(6):563–569.
   PubMed Web of Science ®Google Scholar
• Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70(2 Suppl):S39–47.
   PubMedGoogle Scholar
• Volpe DA, Xu Y, Sahajwalla CG, et al. Methadone metabolism and drug-drug interactions: In Vitro and In Vivo literature review. J Pharm Sci. 2018;107(12):2983–2991.
   PubMed Web of Science ®Google Scholar
• Wahawisan J, Kolluru S, Nguyen T, et al. Methadone toxicity due to smoking cessation–a case report on the drug-drug interaction involving cytochrome P450 isoenzyme 1A2. Ann Pharmacother. 2011;45(6):e34.
   PubMedGoogle Scholar
• Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos. 2003;31(6):742–747.
   PubMed Web of Science ®Google Scholar
• Umeda S, Harakawa N, Yamamoto M, et al. Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6. Biol Pharm Bull. 2005;28(2):212–216.
   PubMed Web of Science ®Google Scholar
• Umehara K, Shimokawa Y, Miyamoto G. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Biol Pharm Bull. 2002;25(5):682–685.
   PubMed Web of Science ®Google Scholar
• Lee M, Silverman SM, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145–161.
   PubMed Web of Science ®Google Scholar
• Athanasos P, Smith CS, White JM, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain. 2006;120(3):267–275.
   PubMed Web of Science ®Google Scholar
• Doverty M, White JM, Somogyi AA, et al. Hyperalgesic responses in methadone maintenance patients. Pain. 2001;90(1–2):91–96.
   PubMed Web of Science ®Google Scholar
• Blinderman CD, Sekine R, Zhang B, et al. Methadone as an analgesic for patients with chronic pain in methadone maintenance treatment programs (MMTPs). J Opioid Manag. 2009;5(2):107–114.
   PubMedGoogle Scholar
• Hay JL, White JM, Bochner F, et al. Hyperalgesia in opioid-managed chronic pain and opioid-dependent patients. J Pain. 2009;10(3):316–322.
   PubMed Web of Science ®Google Scholar
• Peles E, Schreiber S, Gordon J, et al. Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain. 2005;113(3):340–346.
   PubMed Web of Science ®Google Scholar
• Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144(2):127–134.
   PubMed Web of Science ®Google Scholar
• Mitchell AM, Dewey CM. Chronic pain in patients with substance abuse disorder: general guidelines and an approach to treatment. Postgrad Med. 2008;120(1):75–79.
   PubMed Web of Science ®Google Scholar
• Eyler EC. Chronic and acute pain and pain management for patients in methadone maintenance treatment. Am J Addict. 2013;22(1):75–83.
   PubMed Web of Science ®Google Scholar
• Compton P, Charuvastra VC, Kintaudi K, et al. Pain responses in methadone-maintained opioid abusers. J Pain Symptom Manage. 2000;20(4):237–245.
   PubMed Web of Science ®Google Scholar
• Doverty M, Somogyi AA, White JM, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain. 2001;93(2):155–163.
   PubMed Web of Science ®Google Scholar
• Peles E, Schreiber S, Hetzroni T, et al. The differential effect of methadone dose and of chronic pain on pain perception of former heroin addicts receiving methadone maintenance treatment. J Pain. 2011;12(1):41–50.
   PubMed Web of Science ®Google Scholar
• Zahari Z, Lee CS, Ibrahim MA, et al. Relationship between serum methadone concentration and cold pressor pain sensitivity in patients undergoing methadone maintenance therapy. Iran J Pharm Res. 2018;17(Suppl):8–16.
   PubMedGoogle Scholar
• Voon P, Hayashi K, Milloy MJ, et al. Pain among high-risk patients on methadone maintenance treatment. J Pain. 2015;16(9):887–894.
   PubMed Web of Science ®Google Scholar
• Brewer DD, Catalano RF, Haggerty K, et al. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction. 1998;93(1):73–92.
   PubMed Web of Science ®Google Scholar
• Mancino M, Curran G, Han X, et al. Predictors of attrition from a national sample of methadone maintenance patients. Am J Drug Alcohol Abuse. 2010;36(3):155–160.
   PubMed Web of Science ®Google Scholar
• Dhingra L, Masson C, Perlman DC, et al. Epidemiology of pain among outpatients in methadone maintenance treatment programs. Drug Alcohol Depend. 2013;128(1–2):161–165.
   PubMed Web of Science ®Google Scholar
• Dhingra L, Perlman DC, Masson C, et al. Longitudinal analysis of pain and illicit drug use behaviors in outpatients on methadone maintenance. Drug Alcohol Depend. 2015;149:285–289.
   PubMed Web of Science ®Google Scholar
• Yang YJ, Xu YM, Chen WC, et al. Prevalence of pain and its socio-demographic and clinical correlates among heroin-dependent patients receiving methadone maintenance treatment. Sci Rep. 2017;7(1):8840.
   PubMedGoogle Scholar
• Taveros MC, Chuang EJ. Pain management strategies for patients on methadone maintenance therapy: a systematic review of the literature. BMJ Support Palliat Care. 2017;7(4):383–389.
   PubMed Web of Science ®Google Scholar
• Hines S, Theodorou S, Williamson A, et al. Management of acute pain in methadone maintenance therapy in-patients. Drug Alcohol Rev. 2008;27(5):519–523.
   PubMed Web of Science ®Google Scholar
• Hoffman M, Provatas A, Lyver A, et al. Pain management in the opioid-addicted patient with cancer. Cancer. 1991;68(5):1121–1122.
   PubMed Web of Science ®Google Scholar
• Manfredi PL, Gonzales GR, Cheville AL, et al. Methadone analgesia in cancer pain patients on chronic methadone maintenance therapy. J Pain Symptom Manage. 2001;21(2):169–174.
   PubMed Web of Science ®Google Scholar
• Ostgathe C, Gaertner J, Nauck F, et al. High dose levo-methadone treatment for cancer pain in a patient with a history of drug addiction. J Pain Symptom Manage. 2008;35(3):229–231.
   PubMed Web of Science ®Google Scholar
• Rowley D, McLean S, O’Gorman A, et al. Review of cancer pain management in patients receiving maintenance methadone therapy. Am J Hosp Palliat Care. 2011;28(3):183–187.
   PubMed Web of Science ®Google Scholar
• Sulistio M, Jackson K. Three weeks from diagnosis to death: the chaotic journey of a long-term methadone maintenance patient with terminal cancer. J Pain Symptom Manage. 2013;46(4):598–602.
   PubMed Web of Science ®Google Scholar
• Walley AY, Paasche-Orlow M, Lee EC, et al. Acute care hospital utilization among medical inpatients discharged with a substance use disorder diagnosis. J Addict Med. 2012;6(1):50–56.
   PubMed Web of Science ®Google Scholar
• Donroe JH, Holt SR, Tetrault JM. Caring for patients with opioid use disorder in the hospital. CMAJ = Journal De l’Association Medicale Canadienne. 2016;188(17–18):1232–1239.
   PubMed Web of Science ®Google Scholar
• Smith SR, Deshpande BR, Collins JE, et al. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. 2016;24(6):962–972.
   PubMed Web of Science ®Google Scholar
• Abdel Shaheed C, Maher CG, Williams KA, et al. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis. JAMA Intern Med. 2016;176(7):958–968.
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ (Clin Res Ed). 2011;342:c7086.
   PubMed Web of Science ®Google Scholar
• Marschall U, L’Hoest H, Radbruch L, et al. Long-term opioid therapy for chronic non-cancer pain in Germany. Eur J Pain. 2016;20(5):767–776.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–2529.
   PubMed Web of Science ®Google Scholar
• Voon P, Callon C, Nguyen P, et al. Self-management of pain among people who inject drugs in Vancouver. Pain Manag. 2014;4(1):27–35.
   PubMedGoogle Scholar
• Okoli CTC, Al-Mrayat YD, Shelton CI, et al. A retrospective analysis of the association between providing nicotine replacement therapy at admission and motivation to quit and nicotine withdrawal symptoms during an inpatient psychiatric hospitalization. Addict Behav. 2018;85:131–138.
   PubMed Web of Science ®Google Scholar
• Scimeca MM, Savage SR, Portenoy R, et al. Treatment of pain in methadone-maintained patients. Mt Sinai J Med. 2000;67(5–6):412–422.
   PubMedGoogle Scholar
• Goel A, Azargive S, Lamba W, et al. The perioperative patient on buprenorphine: a systematic review of perioperative management strategies and patient outcomes. Can J Anaesth. 2019;66(2):201–217.
   PubMed Web of Science ®Google Scholar
• Dunn KE, Brooner RK, Clark MR. Severity and interference of chronic pain in methadone-maintained outpatients. Pain Med. 2014;15(9):1540–1548.
   PubMed Web of Science ®Google Scholar
• Macintyre PE, Russell RA, Usher KA, et al. Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy. Anaesth Intensive Care. 2013;41(2):222–230.
   PubMed Web of Science ®Google Scholar
• Sen S, Arulkumar S, Cornett EM, et al. New pain management options for the surgical patient on methadone and buprenorphine. Curr Pain Headache Rep. 2016;20(3):16.
   PubMed Web of Science ®Google Scholar
• Huhn AS, Strain EC, Bigelow GE, et al. Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals. Anesthesiology. 2019;130(1):131–141.
   PubMed Web of Science ®Google Scholar
• Schuning J, Schwarzer A. Pharmacological basis of pain treatment. Dtsch Med Wochenschr. 2018;143(19):1363–1371.
   PubMed Web of Science ®Google Scholar
• Huxtable CA, Roberts LJ, Somogyi AA, et al. Acute pain management in opioid-tolerant patients: a growing challenge. Anaesth Intensive Care. 2011;39(5):804–823.
   PubMed Web of Science ®Google Scholar
• Lotsch J, Skarke C, Tegeder I, et al. Drug interactions with patient-controlled analgesia. Clin Pharmacokinet. 2002;41(1):31–57.
   PubMed Web of Science ®Google Scholar
• Andrade S, Bartels DB, Lange R, et al. Safety of metamizole: a systematic review of the literature. J Clin Pharm Ther. 2016;41(5):459–477.
   PubMed Web of Science ®Google Scholar
• Grosser T, Ricciotti E, FitzGerald GA. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci. 2017;38(8):733–748.
   PubMed Web of Science ®Google Scholar
• Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821–847.
   PubMed Web of Science ®Google Scholar
• Garcia-Henares JF, Moral-Munoz JA, Salazar A, et al. Effects of ketamine on postoperative pain after remifentanil-based anesthesia for major and minor surgery in adults: a systematic review and meta-analysis. Front Pharmacol. 2018;9:921.
   PubMed Web of Science ®Google Scholar
• Wang L, Johnston B, Kaushal A, et al. Ketamine added to morphine or hydromorphone patient-controlled analgesia for acute postoperative pain in adults: a systematic review and meta-analysis of randomized trials. Can J Anaesth. 2016;63(3):311–325.
   PubMed Web of Science ®Google Scholar
• Nielsen RV, Fomsgaard JS, Nikolajsen L, et al. Intraoperative S-ketamine for the reduction of opioid consumption and pain one year after spine surgery: A randomized clinical trial of opioid dependent patients. Eur J Pain. 2019 Mar;23(3):455–460.
   Web of Science ®Google Scholar
• Anaya AMC, Choi JK, Lee CS, et al. Ketamine infusion therapy for chronic pain management in South Korea: A national survey for pain physicians with a narrative review. Medicine (Baltimore). 2018;97(32):e11709.
   PubMed Web of Science ®Google Scholar
• Webster LR, Walker MJ. Safety and efficacy of prolonged outpatient ketamine infusions for neuropathic pain. Am J Ther. 2006;13(4):300–305.
   PubMedGoogle Scholar
• Rigo FK, Trevisan G, Godoy MC, et al. Management of neuropathic chronic pain with methadone combined with ketamine: a randomized, double blind, active-controlled clinical trial. Pain Physician. 2017;20(3):207–215.
   PubMed Web of Science ®Google Scholar
• Sanchez Munoz MC, De Kock M, Forget P. What is the place of clonidine in anesthesia? Systematic review and meta-analyses of randomized controlled trials. J Clin Anesth. 2017;38:140–153.
   PubMed Web of Science ®Google Scholar
• Blaudszun G, Lysakowski C, Elia N, et al. Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012;116(6):1312–1322.
   PubMed Web of Science ®Google Scholar
• Wilens T, Zulauf C, Ryland D, et al. Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. Am J Addict. 2015;24(2):173–177.
   PubMed Web of Science ®Google Scholar
• Cotton BP, Bryson WC, Lohman MC, et al. Characteristics of medicaid recipients in methadone maintenance treatment: a comparison across the lifespan. J Subst Abuse Treat. 2018;92:40–45.
   PubMed Web of Science ®Google Scholar
• Bakker A, Streel E. Benzodiazepine maintenance in opiate substitution treatment: good or bad? A retrospective primary care case-note review. J Psychopharmacol. 2017;31(1):62–66.
   PubMed Web of Science ®Google Scholar
• Launonen E, Alho H, Kotovirta E, et al. Diversion of opioid maintenance treatment medications and predictors for diversion among finnish maintenance treatment patients. Int J Drug Policy. 2015;26(9):875–882.
   PubMed Web of Science ®Google Scholar
• Arango-Davila CA, Rincon-Hoyos HG. Depressive disorder, anxiety disorder and chronic pain: multiple manifestations of a common clinical and pathophysiological core. Rev Colomb Psiquiatr. 2018;47(1):46–55.
   PubMedGoogle Scholar
• Zis P, Daskalaki A, Bountouni I, et al. Depression and chronic pain in the elderly: links and management challenges. Clin Interv Aging. 2017;12:709–720.
   PubMed Web of Science ®Google Scholar
• Jackson JL, Mancuso JM, Nickoloff S, et al. Tricyclic and tetracyclic antidepressants for the prevention of frequent episodic or chronic tension-type headache in adults: a systematic review and meta-analysis. J Gen Intern Med. 2017;32(12):1351–1358.
   PubMed Web of Science ®Google Scholar
• Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol. 2012;52(1):6–17.
   PubMed Web of Science ®Google Scholar
• Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician. 2005;71(3):483–490.
   PubMed Web of Science ®Google Scholar
• Miller A, Rabe-Jablonska J. The effectiveness of antidepressants in the treatment of chronic non-cancer pain–a review. Psychiatr Pol. 2005;39(1):21–32.
   PubMedGoogle Scholar
• Mattia C, Paoletti F, Coluzzi F, et al. New antidepressants in the treatment of neuropathic pain. A review. Minerva Anestesiol. 2002;68(3):105–114.
   PubMedGoogle Scholar
• Cairns R, Schaffer AL, Ryan N, et al. Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings. Addiction. 2019 Jun;114(6):1026–1034.
   Web of Science ®Google Scholar
• Bonnet U, Richter EL, Isbruch K, et al. On the addictive power of gabapentinoids: a mini-review. Psychiatr Danub. 2018;30(2):142–149.
   PubMed Web of Science ®Google Scholar
• Al-Husseini A, Wazaify M, Van Hout MC. Pregabalin misuse and abuse in jordan: a qualitative study of user experiences. Int J Ment Health Addict. 2018;16(3):642–654.
   PubMed Web of Science ®Google Scholar
• Bonnet U, Scherbaum N. On the risk of dependence on gabapentinoids. Fortschr Neurol Psychiatr. 2018;86(2):82–105.
   PubMed Web of Science ®Google Scholar
• Zellner N, Eyer F, Zellner T. Alarming pregabalin abuse in munich: prevalence, patterns of use and complications. Dtsch Med Wochenschr. 2017;142(19):e140–e7.
   PubMed Web of Science ®Google Scholar
• Ho KKN, Ferreira PH, Pinheiro MB, et al. Sleep interventions for osteoarthritis and spinal pain: a systematic review and meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2019 Feb;27(2):196–218.
   PubMed Web of Science ®Google Scholar
• Mathias JL, Cant ML, Burke ALJ. Sleep disturbances and sleep disorders in adults living with chronic pain: a meta-analysis. Sleep Med. 2018;52:198–210.
   PubMed Web of Science ®Google Scholar
• Hauser W, Finn DP, Kalso E, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9):1547–1564.
   PubMed Web of Science ®Google Scholar
• Mucke M, Phillips T, Radbruch L, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3:Cd012182.
   PubMedGoogle Scholar
• Sharon H, Goldway N, Goor-Aryeh I, et al. Personal experience and attitudes of pain medicine specialists in Israel regarding the medical use of cannabis for chronic pain. J Pain Res. 2018 Jul 31;11:1411–1419.
   Google Scholar
• Rock EM, Limebeer CL, Parker LA. Effect of cannabidiolic acid and (9)-tetrahydrocannabinol on carrageenan-induced hyperalgesia and edema in a rodent model of inflammatory pain. Psychopharmacology (Berl). 2018;235:3259–3271.
   Web of Science ®Google Scholar
• Tang WX, Zhang LF, Ai YQ, et al. Efficacy of Internet-delivered cognitive-behavioral therapy for the management of chronic pain in children and adolescents: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97(36):e12061.
   PubMed Web of Science ®Google Scholar
• Fisher E, Law E, Palermo TM, et al. Psychological therapies (remotely delivered) for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2015;3:Cd011118.
   PubMedGoogle Scholar
• Bao J, Zhang L, Ning Z, et al. Status investigation of outpatients receiving Methadone Maintenance Treatment (MMT) in Shanghai from 2005 to 2016. Shanghai Arch Psychiatry. 2017;29(6):343–351.
   PubMedGoogle Scholar
• Siuda ER, Carr R 3rd, Rominger DH, et al. Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics. Curr Opin Pharmacol. 2017;32:77–84.
   PubMed Web of Science ®Google Scholar
• Kelly E. Efficacy and ligand bias at the mu-opioid receptor. Br J Pharmacol. 2013;169(7):1430–1446.
   PubMed Web of Science ®Google Scholar
• Preston KL, Bigelow GE, Liebson IA. Antagonist effects of nalbuphine in opioid-dependent human volunteers. J Pharmacol Exp Ther. 1989;248(3):929–937.
   PubMed Web of Science ®Google Scholar
• Strain EC, Preston KL, Liebson IA, et al. Precipitated withdrawal by pentazocine in methadone-maintained volunteers. J Pharmacol Exp Ther. 1993;267(2):624–634.
   PubMed Web of Science ®Google Scholar
• Preston KL, Bigelow GE, Liebson IA. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. J Pharmacol Exp Ther. 1988;246(2):441–448.
   PubMed Web of Science ®Google Scholar
• Hammig R, Kemter A, Strasser J, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99–105.
   PubMed Web of Science ®Google Scholar
• Strain EC, Preston KL, Liebson IA, et al. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther. 1992;261(3):985–993.
   PubMed Web of Science ®Google Scholar
• Webster L, Gruener D, Kirby T, et al. Evaluation of the tolerability of switching patients on chronic full mu-opioid agonist therapy to buccal buprenorphine. Pain Med. 2016 Feb 25. pii: pnv110. [Epub ahead of print].
   Web of Science ®Google Scholar
• McNicol ED, Ferguson MC, Schumann R. Methadone for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;5:Cd012499.
   PubMed Web of Science ®Google Scholar
• Connolly I, Zaleon C, Montagnini M. Management of severe neuropathic cancer pain: an illustrative case and review. Am J Hosp Palliat Care. 2013;30(1):83–90.
   PubMed Web of Science ®Google Scholar
• Daitch J, Frey ME, Silver D, et al. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician. 2012;15(3 Suppl):Es59–66.
   PubMed Web of Science ®Google Scholar
• Fishman MA, Kim PS. Buprenorphine for chronic pain: a systemic review. Curr Pain Headache Rep. 2018;22(12):83.
   PubMed Web of Science ®Google Scholar
• Hale M, Urdaneta V, Kirby MT, et al. Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids. J Pain Res. 2017;10:233–240.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2018: Trends and Developments. Luxembourg: Publications Office of the European Union; 2018 cited 2019 Jul 31. Available from: http://www.emcdda.europa.eu/system/files/publications/8585/20181816_TDAT18001ENN_PDF.pdf
   Google Scholar